Selected article for: "antigen detection and clinical laboratory"

Title: 2016 ACVIM Forum Research Abstract Program
  • Document date: 2016_5_31
  • ID: 2y1y8jpx_407
    Snippet: In phase three of the testing methodology, clinical samples sent to the laboratory were typed for the DEA 5 antigen to establish an incidence rate. Over a period of two months, the laboratory used convenience sampling to test for the DEA 5 antigen. At the closing of phase three, a total of 777 random canine samples were tested, with a total of 63 canines testing positive for the DEA 5 antigen, resulting in an incidence rate of 8.1 %, consistent w.....
    Document: In phase three of the testing methodology, clinical samples sent to the laboratory were typed for the DEA 5 antigen to establish an incidence rate. Over a period of two months, the laboratory used convenience sampling to test for the DEA 5 antigen. At the closing of phase three, a total of 777 random canine samples were tested, with a total of 63 canines testing positive for the DEA 5 antigen, resulting in an incidence rate of 8.1 %, consistent with previously known incidence rates. Therefore, at the conclusion of phase three, it was determined the novel antisera was valid for the detection of the DEA 5 antigen.

    Search related documents:
    Co phrase search for related documents